CTAG2 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 0 are open and 2 are closed. Of the trials that contain CTAG2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [4].

CTAG2 is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CTAG2 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CTAG2 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CTAG2 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CTAG2 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTAG2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CTAG2 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CTAG2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CTAG2 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CTAG2 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].